Pfizer sold 640 million shares in Haleon for 380p each, reducing its holding in the consumer healthcare firm by 7.6% ...

In a report released today, Guillaume Delmas from UBS maintained a Buy rating on Haleon PLC (HLN – Research Report), with a price target ...

Pharmaceutical giant Pfizer Inc. announced on Tuesday that it has reduced its stake in British consumer healthcare company ...

US pharmaceutical giant Pfizer concluded its second sell-down in its consumer healthcare spin-off, Haleon. It raised £2.432bn ...

Following a similar move in March, Pfizer is offloading another tranche of Haleon shares. | Pfizer has sold 640 million ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

The latest health news highlights include Kailera Therapeutics' $400 million funding, potential CVS Health restructuring, ...

Pfizer sold a stake in British consumer healthcare group Haleon worth about $3.26 billion on Monday, cutting its shareholding ...

Pfizer (PFE) reduces its stake in Haleon to 15% from 22.6% by selling £2.45B worth of shares, continuing its gradual ...

Pfizer has divested a $3.3 billion stake in Haleon, reducing its holding in the British consumer healthcare company.

Pfizer, a New York-based pharmaceuticals firm, sold 640 million Haleon shares at 380 pence per share in a placing run by Goldman Sachs International and BofA Securities as joint global coordinators.

Pfizer said, further to the Launch Announcement on 30 September 2024, it has sold 640 million ordinary shares in Haleon plc, at a ...